KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $156.2 million.

  • Halozyme Therapeutics' Accumulated Expenses rose 2121.99% to $156.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $156.2 million, marking a year-over-year increase of 2121.99%. This contributed to the annual value of $156.2 million for FY2025, which is 2121.99% up from last year.
  • Halozyme Therapeutics' Accumulated Expenses amounted to $156.2 million in Q4 2025, which was up 2121.99% from $111.2 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Accumulated Expenses registered a high of $156.2 million during Q4 2025, and its lowest value of $16.1 million during Q1 2021.
  • Its 5-year average for Accumulated Expenses is $85.6 million, with a median of $98.1 million in 2022.
  • In the last 5 years, Halozyme Therapeutics' Accumulated Expenses crashed by 3995.75% in 2021 and then surged by 33634.43% in 2022.
  • Halozyme Therapeutics' Accumulated Expenses (Quarter) stood at $24.4 million in 2021, then soared by 308.17% to $99.8 million in 2022, then grew by 0.92% to $100.7 million in 2023, then grew by 27.98% to $128.9 million in 2024, then rose by 21.22% to $156.2 million in 2025.
  • Its Accumulated Expenses stands at $156.2 million for Q4 2025, versus $111.2 million for Q3 2025 and $115.6 million for Q2 2025.